Anavex Life Sciences Corp (AVXL)

[frrol]

We don't "own" those two compounds and our 2-73 license is limited, which has restricted the IP we are getting granted by POs. The 'missing' IP has been reserved by the owner and inventor. This language isn't "boilerplate"; it does not appear in all other biotechs' filings.

10-K: "U.S. patents related to ANAVEX®2-73 are directed to a dosage form comprising certain doses of ANAVEX®2-73 and donepezil, and the coverage is limited to the United States only. We may not be able to obtain patent protection for ANAVEX®2-73 as a single drug or in other jurisdictions."

Licensing compounds is a very typical arrangement in biotech. The owner is commonly a university or other biotech. (In our case it is individuals, from Greece incidentally). The licensing usually includes assignments of all current patents, though for 2-73 it's a legal sticking point. The Greek and single-drug patents have been reserved.